Drug Profile
Research programme: CFTR inhibitors - Napo Pharmaceuticals
Latest Information Update: 13 Dec 2017
Price :
$50
*
At a glance
- Originator Napo Pharmaceuticals
- Developer Napo Pharmaceuticals; National Institute of Allergy and Infectious Diseases; SRI International; University of California at San Francisco
- Class Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diarrhoea
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diarrhoea in USA
- 06 May 2009 Preclinical trials in Diarrhoea in USA (unspecified route)